This GEN Live show will bring together a panel of leading experts to break down the latest advances, innovations, and challenges shaping genome editing.

AI‑guided analysis surfaces a new CAR T target with multi‑cancer activity, as Penn researchers validate GPNMB‑directed CAR T cells in preclinical models.

Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life ...

The discussion covered plans to increase the agency's headcount and to expedite early through late-stage clinical development in the U.S.

Discoveries may help to explain why some bacteria are hard to eliminate, and also point to potential future approaches to improving antibiotic effectiveness.

Researchers say newly identified cholesterol control pathway is completely separate from anything targeted by existing drugs.

The physical AI platform, named AI Experimentalist, translates research goals from natural language into experiments at scale.

For NK cell expansion, engineered ARH-77 cells may end the current bottleneck by increasing yield by more than 100,000-fold in one month.

Ireland’s National Institute for Bioprocessing Research and Training is the latest member of the WHO’s biomanufacturing training network.

Researchers advance scalable stem-cell bioprocessing with AI-enabled manufacturing for regenerative medicine therapies.

This GEN Spotlight on RNA Therapeutics brings you three interlinked sessions that feature outstanding researchers exploring various aspects of RNA biology and therapeutics.

Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has filed for Chapter 11 bankruptcy protection and agreed to sell some of its programs and platforms to Eli Lilly and ...